Serious adverse events at 1 week to 1 year Assessed via self‐report and medical records · People who smoke cigarettes
Nicotine EC showed no clear difference in serious adverse events at 1 week to 1 year Assessed via self‐report… compared with non‐nicotine EC (low certainty).
1 finding from 1 review
Serious adverse events at 4 weeks to 1 year Assessed via self‐report and medical records · people who smoke
Nicotine EC showed no clear difference in serious adverse events at 4 weeks to 1 year Assessed via self‐report… compared with NRT (low certainty).
1 finding from 1 review
Serious adverse events – measured by self‐report and medical records · people who smoke
It is very uncertain whether nicotine EC changes serious adverse events at 4 weeks to 8 months Assessed via… compared with behavioural support only/no support (very low certainty).
1 finding from 1 review
Adverse events (serious and nonserious) Medical Dictionary for Regulatory Activities (MedDRA) · patients with paroxysmal nocturnal hemoglobinuria
Eculizumab showed no clear difference in adverse events (serious and nonserious) Medical Dictionary for… compared with placebo (low certainty).
1 finding from 1 review
Adverse events Assessed the severe medical complications and exercise‐related musculoskeletal pain · adult lung transplant recipients
1 finding from 1 review
Intervention not reported
Major adverse events** ‒short‐term (> 2 weeks but ≤ 3 months) Major adverse events provided as the proportion of patients reporting any untoward medical occurrence after an epidural injection with hospitalizations. · lumbosacral radicular pain
1 finding from 1 review
Intervention not reported
Minor adverse events** ‒short‐term (> 2 weeks but ≤ 3 months) Minor adverse events provided as the proportion of patients reporting any untoward medical occurrence after an epidural injection without hospitalisations. · lumbosacral radicular pain
It is very uncertain whether the intervention changes minor adverse events** ‒short‐term (> 2 weeks but ≤ 3 months) Minor… (very low certainty).
1 finding from 1 review
Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events · pre‐registration medical students
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events · pre‐registration medical students
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events · pre‐registration medical students
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events · pre‐registration medical students
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · patients with maintenance of medically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Adverse events · Patients with gastro‐oesophageal reflux disease (GORD) in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total adverse events · Induction of Remission in Medically Refractory Crohn's Disease
It is very uncertain whether summary of findings table ‐ Stem Cell changes total Adverse Events compared with placebo or Control (very low certainty).
1 finding from 1 review
Serious adverse events · Induction of Remission in Medically Refractory Crohn's Disease
Summary of findings table ‐ Stem Cell showed no clear difference in serious Adverse Events compared with placebo or Control (low certainty).
1 finding from 1 review
Serious adverse events · patients with maintenance of medically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review